This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Holman, D. H.
Right arrow Articles by Dong, J. Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holman, D. H.
Right arrow Articles by Dong, J. Y.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, November 2009, p. 1624-1632, Vol. 16, No. 11
1071-412X/09/$08.00+0     doi:10.1128/CVI.00182-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

A Complex Adenovirus-Vectored Vaccine against Rift Valley Fever Virus Protects Mice against Lethal Infection in the Presence of Preexisting Vector Immunity{triangledown}

David H. Holman,1 Adam Penn-Nicholson,1 Danher Wang,1 Jan Woraratanadharm,1 Mary-Katherine Harr,1 Min Luo,1 Ellen M. Maher,1 Michael R. Holbrook,2 and John Y. Dong1,3*

GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464,1 University of Texas Medical Branch, Department of Pathology, 301 University Blvd., Galveston, Texas 77555-0609,2 Medical University of South Carolina, Department of Microbiology and Immunology, 171 Ashley Avenue, BSB201, Charleston, South Carolina 294033

Received 6 May 2009/ Returned for modification 22 June 2009/ Accepted 8 September 2009

Rift Valley fever virus (RVFV) has been cited as a potential biological-weapon threat due to the serious and fatal disease it causes in humans and animals and the fact that this mosquito-borne virus can be lethal in an aerosolized form. Current human and veterinary vaccines against RVFV, however, are outdated, inefficient, and unsafe. We have incorporated the RVFV glycoprotein genes into a nonreplicating complex adenovirus (CAdVax) vector platform to develop a novel RVFV vaccine. Mice vaccinated with the CAdVax-based vaccine produced potent humoral immune responses and were protected against lethal RVFV infection. Additionally, protection was elicited in mice despite preexisting immunity to the adenovirus vector.

* Corresponding author. Mailing address: 600 Seacoast Pkwy., Mount Pleasant, SC 29464. Phone: (843) 884-0120. Fax: (843) 884-0601. E-mail: dongj{at}genphar.com

{triangledown} Published ahead of print on 23 September 2009.

Clinical and Vaccine Immunology, November 2009, p. 1624-1632, Vol. 16, No. 11
1071-412X/09/$08.00+0     doi:10.1128/CVI.00182-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»